The EML1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the EML1 gene has been disrupted to create a loss-of-function model. This product is provided as a heterogeneous pool of Raji B lymphocytes carrying targeted gene disruptions introduced by CRISPR/Cas9-mediated genome editing, enabling functional studies without clonal isolation. The polyclonal format preserves population-level diversity while eliminating EML1 protein expression across the cell pool, making it suitable for investigating microtubule-associated processes in a B-cell lymphoma context.
The Raji cell line was originally derived from a patient with Burkitt lymphoma and is widely used as a suspension-adapted B-lymphocyte model. It is Epstein-Barr virus positive and retains key features of malignant B cells, including rapid proliferation and well-characterized signaling networks. Raji cells are employed extensively in lymphoma biology, immune function studies, and drug discovery due to their reproducible growth characteristics and genetic tractability. Their hematopoietic origin and transformed state provide a relevant background for assessing oncogenic mechanisms dependent on cytoskeletal regulation.
EML1 encodes a microtubule-associated protein that stabilizes microtubules and governs mitotic spindle assembly and neuronal migration. The protein is regulated by phosphorylation through mitotic kinases, with CDK1 and Aurora kinases acting as critical upstream activators. Downstream, EML1 interacts directly with tubulin and other microtubule-associated proteins such as MAP1B and MAP2, contributing to microtubule network organization and spindle dynamics. Through these interactions, EML1 modulates cell division, migration, and positioning, placing it at the intersection of cell cycle control and cytoskeletal remodeling. Its disruption is predicted to impair spindle formation and microtubule-dependent processes, with potential consequences for proliferation and survival.
In the Raji B-lymphoma context, EML1 knockout provides a powerful tool to dissect microtubule-dependent mechanisms underlying hematological malignancies. Dysregulation of microtubule stability and mitotic progression is implicated in lymphomagenesis, and EML1??s role in these processes makes it a candidate for functional interrogation in cancer cell biology. By removing EML1 in an EBV-positive B-cell line, researchers can study how microtubule dynamics influence lymphoma cell proliferation, apoptosis, and drug sensitivity, thereby linking basic cytoskeletal biology to pathological outcomes.
This knockout model supports diverse research applications, including the study of microtubule regulation in B-cell lymphoma, functional analysis of EML1 in cell cycle progression and mitosis, and drug screening for microtubule-targeting agents. Representative assays include Western blotting to confirm EML1 ablation, immunofluorescence to assess microtubule organization, flow cytometry for cell cycle and apoptosis profiling, proliferation assays, and drug sensitivity testing with microtubule inhibitors such as vinca alkaloids or taxanes. Cell adhesion assays may further evaluate migration-related phenotypes. For further details and technical support, please contact Ascent Research.
